arrow_back Back to App

Drug Advertising Restrictions: New Rules for Pharmaceutical Companies

New regulations aim to restrict direct-to-consumer drug advertising. For the first three years after a drug's approval, advertising will be prohibited unless the Secretary of Health deems it beneficial for public health. This ensures citizens receive accurate information about medications without immediate advertising pressure.
Key points
Ban on direct-to-consumer advertising for new drugs for the first 3 years after approval.
Possibility of earlier advertising if the Secretary of Health deems it beneficial for public health.
Potential for advertising bans later if drugs show significant adverse health effects.
Changes aim to better protect public health and limit uncontrolled drug advertising.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1117
Sponsor: Rep. DeLauro, Rosa L. [D-CT-3]
Process start date: 2025-02-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Responsibility in Drug Advertising Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1117.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-07.

What are the main provisions?

Key points include:

  • Ban on direct-to-consumer advertising for new drugs for the first 3 years after approval.
  • Possibility of earlier advertising if the Secretary of Health deems it beneficial for public health.
  • Potential for advertising bans later if drugs show significant adverse health effects.
  • Changes aim to better protect public health and limit uncontrolled drug advertising.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. DeLauro, Rosa L. [D-CT-3].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health